Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

NCT07018050 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG: QLS32015
DRUG: Pomalidomide
DRUG: Dexamethasone
DRUG: QL2109 or Daratumumab
DRUG: Bortezomib
DRUG: Lenalidomide

Sponsor

Qilu Pharmaceutical Co., Ltd.